VA/DoD clinical practice guideline for the management of headache
Ano de publicação: 2022
The VA and DoD Evidence-Based Practice Work Group (EBPWG) was established and
first chartered in 2004, with a mission to advise the VA/DoD Health Executive
Committee “on the use of clinical and epidemiological evidence to improve the health of
the population . . .” across the Veterans Health Administration (VHA) and Defense
Health Agency (DHA), by facilitating the development of CPGs for the VA and DoD
populations. Development and update of VA/DoD CPGs is funded by VA Evidence
Based Practice, Office of Quality and Patient Safety. The system-wide goal of evidencebased CPGs is to improve patient health and wellbeing.
In July 2020, the VA and DoD published a CPG for The Primary Care Management of
Headache (2020 VA/DoD Headache CPG), which was based on evidence reviewed
through March 2019. Since the release of that CPG, the evidence base on Headache
has expanded. Consequently, the EBPWG initiated the update of the 2020 VA/DoD
Headache CPG in 2023. This updated CPG’s use of Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) approach reflects a more rigorous
application of the methodology than previous iterations.(2) Therefore, the strength of
some recommendations may have been modified due to the confidence in the quality of
the supporting evidence (see Evidence Quality and Recommendation Strength).
This CPG provides an evidence-based framework for evaluating and managing care for
individuals living with Headache toward improving clinical outcomes.
Successful implementation of this CPG will:
• Assess the patient’s condition and collaborate with the patient, family, and caregivers to determine optimal management of patient care; • Emphasize the use of patient-centered care and shared decision making; • Minimize preventable complications and morbidity; and • Optimize individual health outcomes and quality of life (QoL).
Headache/drug therapy, Headache/classification, Patient-Centered Care/standards, Transcutaneous Electric Nerve Stimulation, Angiotensin Receptor Antagonists/therapeutic use, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Antidepressive Agents/therapeutic use, Anticonvulsants/therapeutic use, Adrenergic beta-Antagonists/therapeutic use, Headache/therapy